Zhi‐Qiang Wang

机构：Nanjing University of Chinese Medicine, The University of Texas MD Anderson Cancer Center, Sun Yat-sen University, Donghua University, Northeast Normal University, Regeneron (United States), Fudan University, Hebei General Hospital, Guangxi University of Chinese Medicine, First Hospital of Shijiazhuang, Zhongshan Hospital, The First Affiliated Hospital, Sun Yat-sen University, Suzhou Traditional Chinese Medicine Hospital, Sun Yat-sen University Cancer Center, Eighth Affiliated Hospital of Sun Yat-sen University, Shanxi Datong University · ORCID：0000-0003-2658-8781

发表论文 164 篇 · 总被引 3071 次 · h-index 28

代表论文

• Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial (2024 · PLoS Medicine · 被引 19)
• Copper-doped layered double hydroxides co-deliver proteins/drugs for cascaded chemodynamic/immunotherapy via dual regulation of tumor metabolism (2025 · Acta Biomaterialia · 被引 15)
• Novel methyltransferase G9a inhibitor induces ferroptosis in multiple myeloma through Nrf2/HO-1 pathway (2024 · Annals of Hematology · 被引 14)
• A phase IV study to evaluate the safety of fruquintinib in Chinese patients in real-world clinical practice (2024 · The Oncologist · 被引 11)
• Patterns and outcomes of early and late recurrence after hepatectomy for hepatocellular carcinoma with microvascular invasion: a multicenter study in China (2025 · Hepatology International · 被引 10)
• Lumbar disc herniation reabsorption: a review of clinical manifestations, mechanisms, and conservative treatments (2025 · Frontiers in Medicine · 被引 8)